Currently in the Indian pharmaceutical industry there are 24,000 companies competing for a market worth USD 5 billion.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c29907 ) has announced the addition of The Indian Pharmaceutical Industry to their offering

The Indian pharmaceutical industry grew at a very slow pace from 1947 to 1970, largely due to the lack of incentives and the failure of the government to set-up a concrete regulatory framework.

The environment under which the Indian pharmaceutical industry is operating is changing very slowly at present, but is likely to change significantly - and significantly faster - in the future.

Today, the industry is characterized by numerous governmental regulations and policy changes, stifling price controls, rigorous controls on formulations, and an absence of international patent protection. During 1970, the Indian Patents Act (IPA) and the Drug Price Control Order (Dpco) were passed. Although the Dpco acted as a buffer against pharmaceutical companies making free pricing illegal, it fulfilled the goal of providing quality drugs to the public at reasonable rates.

The introduction of the IPA - which did not recognize product patents but only process patents - provided a major thrust to the industry and its companies, which, through the process of reverse-engineering, began to produce bulk drugs and formulations at lower costs. This led to high fragmentation in the industry, due to the emergence of a number of small firms.

Thus, there are today about 24,000 companies - big, medium and small - fighting for a USD 5 Billion market. Out of these around 300 are in the organized sector, around 15,000 being in the small scale sector and the remaining being very small without any economies of scale.

India manufactures over 400 bulk drugs and around 60,000 formulations, which are distributed by 5,000,000 chemists all over the country.

The Indian pharmaceutical industry is passing through a wave of consolidation, with the objective to strengthen their brand equity and distribution in what is essentially a branded-generics market.

In the period 1995-98, the Indian Pharma industry witnessed as many as 20 mergers, acquisitions and takeovers. During the same period, globally the pharmaceutical industry also witnessed mega mergers.

Topics Covered
1. Overview
2. Introduction
3. The Indian Market
4. Characteristics of the Indian Pharmaceutical Industry
5. Key Players in the Indian Pharmaceutical Industry
6. Strategic Groups
7. Critical Success Factors (CSF) of the Industry
8. A Farsighted Strategy in Competition and Cooperation
9. Indian Pharma Exports
10. Policies and Regulations
11. Changing Scenario of Product Patent Regime
12. Laws Pertaining to Manufacture and Sale of Drugs in India
13. Marketing and Distribution in the Pharmaceutical Industry
14. The Changing External Environment
15. Porters Five Forces Model
16. Future Outlook for the Indian Pharmaceutical Industry
17. Emerging Trends
18. India--The Clinical Trial Destination
19. Risks--Weaknesses and Threats--Faced by Indian Industry
20. Intellectual Property and Access to Medicines
21. Evolving Indian Drug Research and Development
22. Case of a Leading Indian Firm--Ranbaxy Laboratories
23. Strategic Options for Pharmaceutical Firms
24. How to Build Sustainable Competitive Advantage

Summary

The purpose of this study is to describe the specific segment of the pharmaceutical market sector called the Indian pharmaceutical industry. This sector includes all of the generally accepted pharmaceutical manufacturing activities that are currently used today, including the bulk drug industry, formulations and major therapeutic segments. It examines these clinical supplies as utilized in hospitals, clinics and doctor's offices.

For more information visit http://www.researchandmarkets.com/reports/c29907